Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Delvys Rodríguez‐Abreu, Steven Francis Powell, Maximilian Johannes Hochmair et al. · Annals of Oncology · 2021
Cited by 415 works. doi:10.1016/j.annonc.2021.04.008 Open-access PDF
Authors
- Delvys Rodríguez‐Abreu
- Steven Francis Powell
- Maximilian Johannes Hochmair
- Shirish M. Gadgeel
- Emilio Esteban
- Enriqueta Felip
- Giovanna Speranza
- Flávia De Angelis
- Manuel Dómine
- Susanna Yee-Shan Cheng
- Helge G. Bischoff
- Nir Peled
- Martin Reck
- Edward B. Garon
- Michael Joseph Boyer
- Takayasu Kurata
- Jing Liang Yang
- Maria Catherine Pietanza
References
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study